Olivier Elemento, PhD, is the Director at the Englander Institute for Precision Medicine at Weill Cornell Medicine, a large multi-disciplinary institute that uses precision medicine technologies and informatics to uncover the molecular mechanisms of disease and individualize disease treatment and prevention. In addition, he is a full Professor of Systems and Computational Biomedicine, Associate Director of the Institute for Computational Biomedicine at Weill Cornell Medical College, and Associate Director of the Clinical and Translational Science Center at Weill Cornell Medical College. Dr. Elemento’s research group combines Big Data, Artificial Intelligence with experimentation and genomic profiling to accelerate the discovery of cancer cures. Dr. Elemento and his team have published over 500 scientific papers in the area of precision medicine, genomics, epigenomics, artificial intelligence, computational biology and drug discovery. He is a recipient of awards including the NSF CAREER Award, Siegel Family Award for Outstanding Medical Research, the Irma T. Hirschl Career Scientist Award and the Daedalus Fund for Innovation Award. His research group has developed new assays and analytical pipelines for cancer genome and epigenome analysis, clinical sequencing and precision medicine. They led the development of the first New York State approved whole exome sequencing test for oncology and pioneered new methods for assessing tumor-driving pathways, the immune landscape of tumors and predicting immunotherapy responders. In addition, Dr. Elemento and his lab developed methodologies to repurpose existing drugs to target specific pathways, predict drug toxicity and identify synergistic drug combinations. His research has been highlighted in broad audience media outlets, including the New York Times Magazine, NPR, Wired, Popular Science, CBS, Gizmodo, and Huffington Post.